Latest News about RHHBY
Recent news which mentions RHHBY
From Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
February 27, 2025
From Motley Fool
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
January 28, 2025
From Benzinga
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
January 27, 2025
From Benzinga
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
January 21, 2025
From Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
January 16, 2025
From Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
December 31, 2024
From Benzinga
Roche CEO Reassures No Job Cuts Despite Challenges: Report
December 30, 2024
From Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
December 19, 2024
From Benzinga
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
December 18, 2024
From Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
December 13, 2024
From Benzinga
From Benzinga
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
November 26, 2024
From Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
From Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
October 30, 2024
From Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
From Benzinga
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
October 15, 2024
From Benzinga
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
From Benzinga
From Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
October 08, 2024
From Benzinga
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
From Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
From Motley Fool
From Benzinga
3 Top Stocks That Could Still Rocket Higher in 2024
October 04, 2024
From Motley Fool
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
From Benzinga
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
September 19, 2024
From Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
From Motley Fool
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
September 16, 2024
From Benzinga
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
September 13, 2024
From Motley Fool
Why Roche Holdings Stock Withered on Wednesday
September 11, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.